Korecyte Bio is a biotech startup based in the Netherlands with R&D activities in London, UK. Our mission is to develop safer and more effective cellular immunotherapies. Our genetic construct, a synergistic dual-oxygen sensing CAR-switching technology,  allows CAR-expression only in low-oxygen conditions, as present in most solid tumours, and inhibits CAR expression in healthy tissue, avoiding toxicities and allowing broad tumour targeting. Moreover, cellular exhaustion is prevented, leaving full tumour killing potential. Our platform technology can be used in any cell type and in any CAR construct, including armouring. A phase I/IIa trial is planned to validate the technology and we foresee great potential for co-development and licensing.